Effect of Psychoactive Drugs on Behavior Induced by 2-Phenylethylamine in Rats
2-Phenylethylamine (PEA) combines 2 features which are important for the behavioral pharmacologist interested in the characterization of monoamine oxidase (MAO) inhibitors in rats: It is degraded rather specifically by the B-form of MAO (Yang and Neff 1974) and produces stereotyped behavior in rodents. Several authors have shown that the intensity of stereotyped behavior is greatly increased by inhibitors of the B-type of MAO, while MAO-A inhibitors were much less active (Braestrup et. al 1975, 1978; Moja et al. 1976). We tried to establish a behavioral test system in vivo which would allow us to determine the inhibitory specificity of a given compound for the A- or B-type of MAO. The potency of various MAO-inhibitors to potentiate stereotyped behavior induced by PEA was compared with their effect on L-5-hydroxytryptophan (L-HTP)-induced excitation in rats. The latter test has been shown to be specific for MAO-A inhibitors (Ortmann et al. 1980). In addition we compared the behavioral effects of the test compounds in the PEA test with their ability to increase PEA levels of rat brain and to inhibit MAO in an ex vivo assay.
KeywordsReserpine animaLs Tryptamine Padding MOCLOBEMIDE
Unable to display preview. Download preview PDF.
- Braestrup C. and Randrup A. (1978) Stereotyped behavior in rats induced by phenylethylamine, dependence on dopamine and noradrenaline, and possible relation to psychoses? in Noncatecholic Phenylethylamines, eds. A. Mosnaim, M.E. Wolf. Marcel Dekker pp 245–269Google Scholar
- Fischer R.A. (1958) Statistical methods for research workers. 13th edition, Oliver and Boyd Ltd, Edinburgh, p 96Google Scholar
- Wdmeier, P.C., Baumann, P.A., Maftre, L. (1979) CGP 6085 A a new, specific, inhibitor of serotonin uptake: Neurochemical characterization and comparison with other serotonin-uptake blockers. J. Pharm. Exp. Therap. 211,42–49Google Scholar
- Yang H.-Y.T. and Neff N.H. (1974) The Monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J. Pharm. Exp. Therap. 189 733–740Google Scholar